中国实用外科杂志

中国实用外科杂志

• 述评 • 上一篇    下一篇

肝内胆管癌临床研究现状

钦伦秀，王祥宇   

  1. 复旦大学附属华山医院普外科 复旦大学肿瘤转移研究所，上海200040
  • 出版日期:2020-06-01 发布日期:2020-06-24

  • Online:2020-06-01 Published:2020-06-24

摘要： 肝内胆管癌（ICC）的病因复杂，且高度侵袭、高度异质、预后不良。近年来ICC的临床诊断与治疗进展显著，主要包括功能与分子影像学技术提供了更精准的术前评估与复发监测新手段；分子分型与传统临床病理学分型结合为ICC的临床决策提供了更精准保障。手术切除仍是ICC的惟一根治性治疗手段，对R0切除、淋巴结清扫、术后辅助治疗以及复发再切除的意义得到肯定。局部治疗、分子靶向治疗及免疫治疗等新型疗法发展迅速，为晚期ICC带来新的希望。传统治疗手段与新型疗法的序贯、联合，“多兵种联合作战”是未来发展方向。

关键词: 肝内胆管癌, 临床研究

Abstract: Current status in clinical studies of intrahepatic cholangiocarcinoma        QIN Lun-xiu, WANG Xiang-yu.Department of General Surgery, Huashan Hospital & Cancer Metastasis Institute, Fudan University, Shanghai 200040, China
Corresponding author: QIN Lun-xiu,,E-mail：qinlx@fudan.edu.cn
Abstract    Intrahepatic cholangiocarcinoma（ICC）is a highly invasive malignancy with complicated etiologies，and dismal prognosis. Significant progresses in clinical studies of ICC have been obtained recently. Functional and molecular imaging techniques provide more precisive diagnosis，preoperative evaluation and tumor relapse monitoring for ICC.Molecular classification in combination with traditional clinic-pathological classification is helpful in making a precision treatment choice.Surgical resection is the only curative treatment strategy for early stage ICC，but a high probabilities of local regional recurrence and distant metastasis constrain their long-term survival. Strategy systematic chemotherapy remains the first line treatment for late stage ICCs，and effective molecular targeted therapy is still lacking.Immunotherapy，particularly in combination with the other treatment strategies，is a new hope for patients with ICC.

Key words: intrahepatic cholangiocarcinoma, clinical research